China Pharma (NYSE:CPHI) Receives New Coverage from Analysts at started coverage on shares of China Pharma (NYSE:CPHIFree Report) in a research note released on Wednesday. The brokerage issued a hold rating on the stock.

China Pharma Stock Performance

NYSE CPHI opened at $0.29 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.25 and a current ratio of 0.89. China Pharma has a 52-week low of $0.27 and a 52-week high of $2.18. The company has a 50-day simple moving average of $0.34 and a 200 day simple moving average of $0.43.

China Pharma (NYSE:CPHIGet Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $1.37 million for the quarter. China Pharma had a negative net margin of 55.42% and a negative return on equity of 54.31%.

About China Pharma

(Get Free Report)

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.

Further Reading

Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with's FREE daily email newsletter.